Simplicity Wealth LLC raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 20.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 53,267 shares of the company's stock after buying an additional 9,009 shares during the quarter. Simplicity Wealth LLC's holdings in Merck & Co., Inc. were worth $6,845,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Cascade Financial Partners LLC lifted its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock worth $1,895,000 after buying an additional 80 shares in the last quarter. Somerset Trust Co boosted its stake in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock worth $1,118,000 after acquiring an additional 81 shares during the period. Stonebridge Financial Group LLC increased its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after purchasing an additional 81 shares during the last quarter. Stronghold Wealth Management L.L.C. raised its holdings in Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock valued at $416,000 after acquiring an additional 82 shares during the period. Finally, Lederer & Associates Investment Counsel CA lifted its holdings in Merck & Co., Inc. by 0.9% during the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock worth $1,234,000 after purchasing an additional 84 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.
Merck & Co., Inc. Price Performance
Merck & Co., Inc. stock opened at $156.54 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The business's 50 day simple moving average is $129.64 and its 200 day simple moving average is $121.80. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92. The company has a market cap of $386.22 billion, a price-to-earnings ratio of 125.23, a PEG ratio of 6.32 and a beta of 0.19.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.
Merck & Co., Inc. Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.
Insider Transactions at Merck & Co., Inc.
In related news, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company's stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on MRK. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Jefferies Financial Group cut shares of Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Guggenheim increased their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. BMO Capital Markets upped their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an "outperform" rating in a research report on Thursday, August 20th. Finally, The Goldman Sachs Group lifted their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a research note on Friday, August 21st. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and an average price target of $147.60.
Check Out Our Latest Stock Report on Merck & Co., Inc.
Merck & Co., Inc. News Roundup
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
- Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
- Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
- Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
- Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.
Merck & Co., Inc. Company Profile
(
Free Report)
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
